Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:BEAM NASDAQ:MLYS OTCMKTS:NWBO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$37.68-2.0%$38.32$26.20▼$63.50$1.74B1.42716,845 shs150,613 shsBEAMBeam Therapeutics$20.29-0.4%$18.96$13.52▼$35.25$2.05B2.142.16 million shs1.05 million shsMLYSMineralys Therapeutics$37.22-3.3%$16.53$8.24▼$38.57$2.46B-0.291.07 million shs1.32 million shsNWBONorthwest Biotherapeutics$0.25-0.8%$0.25$0.17▼$0.48$374.55M-1.143.47 million shs1.25 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+0.10%+1.58%+8.67%-9.38%-19.05%BEAMBeam Therapeutics+2.11%+24.83%+15.55%+13.81%-12.99%MLYSMineralys Therapeutics+7.15%+33.40%+196.15%+147.59%+225.17%NWBONorthwest Biotherapeutics+0.76%-4.91%+1.61%-3.82%-16.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$37.68-2.0%$38.32$26.20▼$63.50$1.74B1.42716,845 shs150,613 shsBEAMBeam Therapeutics$20.29-0.4%$18.96$13.52▼$35.25$2.05B2.142.16 million shs1.05 million shsMLYSMineralys Therapeutics$37.22-3.3%$16.53$8.24▼$38.57$2.46B-0.291.07 million shs1.32 million shsNWBONorthwest Biotherapeutics$0.25-0.8%$0.25$0.17▼$0.48$374.55M-1.143.47 million shs1.25 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+0.10%+1.58%+8.67%-9.38%-19.05%BEAMBeam Therapeutics+2.11%+24.83%+15.55%+13.81%-12.99%MLYSMineralys Therapeutics+7.15%+33.40%+196.15%+147.59%+225.17%NWBONorthwest Biotherapeutics+0.76%-4.91%+1.61%-3.82%-16.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.88Moderate Buy$97.29158.19% UpsideBEAMBeam Therapeutics 3.07Buy$48.45138.81% UpsideMLYSMineralys Therapeutics 2.80Moderate Buy$42.2013.40% UpsideNWBONorthwest Biotherapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NWBO, MLYS, BEAM, and APGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025MLYSMineralys TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $52.009/8/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.009/3/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$15.00 ➝ $26.008/28/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/28/2025APGEApogee TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$78.00 ➝ $87.008/28/2025MLYSMineralys TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $43.008/14/2025APGEApogee TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.008/11/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$90.008/6/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$25.00 ➝ $21.007/21/2025BEAMBeam TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/ABEAMBeam Therapeutics$60.27M34.06N/AN/A$8.86 per share2.29MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ANWBONorthwest Biotherapeutics$1.38M271.41N/AN/A($0.07) per share-3.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%11/11/2025 (Estimated)BEAMBeam Therapeutics-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.56N/AN/AN/AN/A-70.44%-65.51%11/10/2025 (Estimated)NWBONorthwest Biotherapeutics-$83.78M-$0.06N/A∞N/A-7,524.50%N/A-291.13%11/14/2025 (Estimated)Latest NWBO, MLYS, BEAM, and APGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025NWBONorthwest BiotherapeuticsN/A-$0.01N/A-$0.01N/A$0.13 million8/12/2025Q2 2025MLYSMineralys Therapeutics-$0.78-$0.66+$0.12-$0.66N/AN/A8/11/2025Q2 2025APGEApogee Therapeutics-$1.03-$1.13-$0.10-$1.13N/AN/A8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ABEAMBeam Therapeutics$0.904.42%N/AN/A N/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A16.3616.36BEAMBeam TherapeuticsN/A6.756.75MLYSMineralys TherapeuticsN/A15.1215.12NWBONorthwest BiotherapeuticsN/A0.070.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%BEAMBeam Therapeutics99.68%MLYSMineralys Therapeutics84.46%NWBONorthwest Biotherapeutics0.04%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%BEAMBeam Therapeutics3.50%MLYSMineralys Therapeutics33.24%NWBONorthwest Biotherapeutics8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.11 million26.39 millionOptionableBEAMBeam Therapeutics510101.16 million97.62 millionOptionableMLYSMineralys Therapeutics2866.30 million44.26 millionOptionableNWBONorthwest Biotherapeutics201.50 billion1.37 billionNot OptionableNWBO, MLYS, BEAM, and APGE HeadlinesRecent News About These CompaniesNorthwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.August 27, 2025 | finanznachrichten.deNorthwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.August 27, 2025 | prnewswire.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200 Day Moving Average - Time to Sell?August 24, 2025 | marketbeat.comNorthwest Biotherapeutics announces passing of general counsel Les GoldmanAugust 19, 2025 | msn.comNorthwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les GoldmanAugust 18, 2025 | prnewswire.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Announces Earnings ResultsAugust 16, 2025 | marketbeat.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Passes Below 200-Day Moving Average - Here's WhyAugust 15, 2025 | marketbeat.comNWBO - Northwest Biotherapeutics Inc News - MorningstarJuly 11, 2025 | morningstar.comMNorthwest Biotherapeutics, Inc. (NWBO) - Yahoo FinanceJune 29, 2025 | uk.finance.yahoo.comNWBO Northwest Biotherapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comNorthwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor TreatmentsJune 13, 2025 | finanznachrichten.deNorthwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor TreatmentsJune 11, 2025 | prnewswire.comNorthwest Biotherapeutics: A Spike On Their Expected Imminent ApprovalApril 22, 2025 | seekingalpha.comCitadel Securities, Virtu Must Face Biotech Stock Spoof Suit (1)March 29, 2025 | news.bloomberglaw.comNInvestors Watching Two Small-Caps for News on Potential Major Advancements in Cancer TreatmentsJanuary 13, 2025 | msn.comNorthwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional FinancingDecember 26, 2024 | prnewswire.comNorthwest Biotherapeutics: All Is Not Well With This OneDecember 14, 2024 | seekingalpha.comBehind the Bell: Arcutis BiotherapeuticsNovember 5, 2024 | nasdaq.comNorthwest Registered Agent Review 2024: Features, Pricing & MoreOctober 24, 2024 | forbes.com0K95.IL,0P0000AFQ5,0 (0K95.IL)September 14, 2024 | nz.finance.yahoo.comTraders News Digs into the Biotech Space and Releases New Feature ProfileAugust 15, 2024 | br.advfn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNWBO, MLYS, BEAM, and APGE Company DescriptionsApogee Therapeutics NASDAQ:APGE$37.68 -0.78 (-2.03%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Beam Therapeutics NASDAQ:BEAM$20.29 -0.08 (-0.39%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Mineralys Therapeutics NASDAQ:MLYS$37.22 -1.29 (-3.34%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Northwest Biotherapeutics OTCMKTS:NWBO$0.25 0.00 (-0.79%) As of 01:29 PM EasternNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
